Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan

• Kawashiri, Shin-ya

• Endo, Yushiro

• Nishino, Ayako

• Okamoto, Momoko

• Tsuji, Sosuke

• Takatani, Ayuko

• Shimizu, Toshimasa

• Sumiyoshi, Remi

• Koga, Tomohiro

• Iwamoto, Naoki

• Ichinose, Kunihiro

• Tamai, Mami

• Nakamura, Hideki

• Origuchi, Tomoki

• Aramaki, Toshiyuki

• Ueki, Yukitaka

• Yoshitama, Tamami

• Eiraku, Nobutaka

• Matsuoka, Naoki

• Okada, Akitomo

• Fujikawa, Keita

• Hamada, Hiroaki

• Nagano, Shuji

• Tada, Yoshifumi

• Kawakami, Atsushi

抄録

Background: To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. Methods: We enrolled 59 RA patients treated with abatacept from a multicenter, exploratory, short-term, prospective and observational ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients’ clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. ‘Power Doppler (PD) responder’ was defined as a patient whose Δtotal PD score over 6 months was greater than the median change. Results: Abatacept significantly improved the clinical disease activity and MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the abatacept introduction (p = 0.016). The ΔSOST and ΔOPG were significantly greater in the PD responders versus the non-PD responders (p = 0.0041 and 0.0073, respectively). The serum Dkk-1 at baseline was significantly lower in the PD responders (n = 30) vs. the non-PD responders (n = 29) (p = 0.026). A multivariate logistic regression analysis showed that the serum Dkk-1 at baseline (odds ratio 0.50, 95% confidence interval [CI] 0.23–0.91, p = 0.043) was an independent predictor of PD responder status. Conclusion: Serum levels of bone biomarkers may be useful for predicting RA patients’ therapeutic responses to abatacept. Trial registration: Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort study Trial registration number: UMIN000012524 Date of registration: 12/9/2013 URL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657

BMC Musculoskeletal Disorders, 22, art. no. 506; 2021

収録刊行物

• BMC Musculoskeletal Disorders

  BMC Musculoskeletal Disorders 22 art. no. 506-, 2021-06-01

  BioMed Central Ltd

キーワード

• Rheumatoid arthritis
• Musculoskeletal ultrasound
• Abatacept
• Dickkopf-1
• Osteoprotegerin
• Power Doppler
• Sclerostin

詳細情報

• CRID: 1050289874221857792
• NII論文ID: 120007166818
• ISSN: 14712474
• DOI: 10.1186/s12891-021-04392-5
• HANDLE: 10069/00040991
• Web Site: https://nagasaki-u.repo.nii.ac.jp/records/26822
• Web Site: https://link.springer.com/content/pdf/10.1186/s12891-021-04392-5.pdf
• Web Site: https://link.springer.com/article/10.1186/s12891-021-04392-5/fulltext.html
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • Crossref
  • CiNii Articles
  • KAKEN